Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) has shared an update.
BeOne Medicines Ltd. has announced a series of waivers and exemptions from compliance with certain Hong Kong Stock Exchange Listing Rules and the Companies Ordinance. These include waivers related to the use of US GAAP, placings to connected persons, and collaboration agreements, among others. The company’s directors have taken responsibility for the accuracy of the information provided and have committed to updating the information sheet if there are material changes. This announcement highlights BeOne Medicines’ strategic moves to navigate regulatory requirements, potentially impacting its operational flexibility and stakeholder relations.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 5,487,900
Technical Sentiment Signal: Buy
Current Market Cap: HK$278.3B
Find detailed analytics on 6160 stock on TipRanks’ Stock Analysis page.